Active
    SME

    Goldline Pharmaceutical Ltd

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    Goldline Pharmaceutical Ltd IPO opened on 12 May 2026 and closed on 14 May 2026, with a price band of ₹41–₹43 per share. The IPO had a lot size of 3000 shares, requiring a minimum investment of ₹2,58,000 per lot at the upper price band. The issue size was ₹11.61 crore, and the shares get listed on 19 May 2026.

    Goldline Pharmaceutical Ltd IPO Details

    Listing Date

    19 May 2026

    Bid Price

    ₹41 - ₹43

    Lot Size

    3000 Shares

    Minimum Investment

    ₹2,58,000 / 2 Lots

    Issue Size

    ₹11.61 Cr

    Key Dates to Track

        Here are the important dates you need to know in order to participate in this IPO

    tick

    Offer Start Date

    12th May

    tick

    Offer End Date

    14th May

    tick

    Allotment Date

    15th May

    tick

    Refund Initiation

    18th May

    tick

    Demat Transfer

    18th May

    tick

    Listing Date

    19th May

    About Goldline Pharmaceutical Ltd IPO

    Goldline Pharmaceuticals is engaged in the marketing and distribution of pharmaceutical products under the “Goldline” brand. The company’s portfolio is categorised into five divisions, namely Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. These divisions cater to multiple therapeutic segments including cardiology, diabetology, orthopaedics, paediatrics, neurology, gastroenterology, critical care, and supportive cancer care. As per the company information, the portfolio consists of more than 140 products designed for different medical specialities and healthcare requirements. The company follows an asset-light operating model where medicines are manufactured through third-party manufacturing partners based on its product specifications and market requirements.
     

    The company markets and distributes its products through a network of distributors supplying retailers and wholesalers across multiple states including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar. Goldline Pharmaceuticals currently works with 15 manufacturing partners and 7 distributors for its operations. In addition to product marketing, the company also supports hospitals and healthcare institutions with procurement and material supply services. Its business model is focused on product branding, distribution management, and therapeutic expansion across selected domestic markets while ensuring regulatory compliance and quality standards through third-party manufacturing arrangements.

    Goldline Pharmaceutical Ltd Shareholding Pattern

      Pre-Issue Post-Issue
    Promoter Group 79.7% 57.3%
    Public Group 20.3% 42.7%

    Goldline Pharmaceutical Ltd IPO Reservation

    QIB Shares Offered 5,40,000 (20%)
    NII (HNI) Shares Offered 3,90,000 (14.44%)
    Retail Shares Offered 9,00,000 (33.33%)
    Anchor Investor Shares Offered 7,32,000 (27.11%)
    Total Shares Offered 27,00,000
    Total Shares With Anchor Investor 27,00,000

    Goldline Pharmaceutical Ltd IPO Lot Size

    Application Lots Shares Amount
    Retail (Min) 2 6,000 ₹2,58,000
    Retail (Max) 2 6,000 ₹2,58,000
    S HNI (Min) 3 9,000 ₹3,87,000
    S HNI (Max) 7 21,000 ₹9,03,000
    B HNI (MIN) 8 24,000 ₹10,32,000

    Goldline Pharmaceutical Ltd IPO Anchor Portion Size

    Bid Date May 11, 2026

    Goldline Pharmaceutical Ltd IPO registrar

    Bigshare Services Pvt Ltd
    Phone Number +91 22 6263 8200
    Email Id ipo@bigshareonline.com
    Website www.bigshareonline.com

    Goldline Pharmaceutical Ltd IPO Lead Manager

    1. Cumulative Capital Private Limited

    Goldline Pharmaceutical Ltd Financial Information

    March 31, 2025 March 31, 2024 March 31, 2023
    Net Worth ₹10.35 Cr ₹7.87 Cr ₹5.89 Cr
    Reserves and Surplus ₹1.65 Cr ₹3.76 Cr ₹2.08 Cr
    Total Borrowing ₹11.03 Cr ₹11.13 Cr ₹10.83 Cr

    Goldline Pharmaceutical Ltd IPO Subscription LIVE Status

    Category No. of shares offered No. of shares bid Subscription (Times)
    Qualified Institutional Buyers (QIBs) 5,40,000 9,73,17,000 180.2167
    Non Institutional Investors (NIIs) 5,28,000 64,83,33,000 1,227.9034
    Retail Individual Investors (RIIs) 9,00,000 79,30,38,000 881.1533
    Total 19,68,000 1,53,86,88,000 781.85

    Strength of Goldline Pharmaceutical Ltd

    • Experienced promoters and management team with industry knowledge and a track record.
    • Asset-light business model and competitive products.
    • Scalable Business Model.
    • Wide and diverse range of product offerings.
    • Strong Supplier and Vendor Relationships.
    • Established Distribution Network.

    Risks Involved

    • Its rely entirely on third-party contract manufacturers for the manufacturing of the company pharmaceutical products, and any failure or inability of such manufacturers to meet quality, regulatory, delivery or capacity requirements could adversely affect its business, results of operations and financial condition.
    • The Company has experienced delays in filing e-forms with the Registrar of Companies (RoC) in the past, resulting in the payment of late fees. Further, there have also been instances of erroneous filings made by the Company, in the past. While no regulatory actions or penalties has been imposed to date except below mentioned, there is no assurance that such actions will not be levied in the future. The Company cannot guarantee that similar delays will not occur in the future, and if regulatory authorities impose penalties or take punitive actions against the Company or its directors/officers, it could negatively affect the Company's business and financial condition.
    • The company commercial success is largely dependent upon its ability to analyses the market of new pharmaceutical products, failure of which may has an adverse impact on its revenue and profitability.
    • There has been instances of delays in payment of statutory dues, i.e. GST by the Company. In case of any delay in payment of statutory due in future by the Company, the Regulatory Authorities may impose monetary penalties on it or take certain punitive actions against the Company in relation to the same which may has adverse impact on its business, financial condition and results of operations.
    • Its depend on the company distributors for a significant portion of its revenue, and any decrease in revenues or sales from any one of the company key intermediaries may adversely affect its business and results of operations. the Company has a distribution network of 8 distributors and is dependent on these distributors for a significant portion of its revenue. If the company unable to maintain its relationship with such customers or if there is a reduction in their demand for the company products, its business, results of operations and financial condition will be materially and adversely affected.
    • There are outstanding mitigations involving the Company, Promoters, Directors, Key Managerial Personnel, Senior Management and Group Companies, if determined adversely, may adversely affect its business and financial condition.
    • The company Promoter Group entities Numerius Healthcare Private Limited, Nucleage Lifescience Private Limited and Nucleage Pharma Solutions Private Limited has conflicts of interest as they are engaged in similar business and may compete with it.
    • Its derive a significant portion of the company revenue from certain of its products. If sales volume or price of such products declines in the future, or if the company unable to sell such products for any reason, its business, financial condition, cash flows and results of operations could be adversely affected.
    • The company operate in limited geographies for a significant portion of its revenue and also depends on limited number of customers for the company revenue from operations.
    • The Company had negative cash flows in the past years, details of which are given below. Sustained negative cash flow could impact its growth and business.
    Invest in IPOs with ease

    Sign-in to invest with your demat account, or set up a new demat account for free

    Industry Outlook of Goldline Pharmaceutical IPO

    • The Indian pharmaceutical industry continues to witness growth supported by rising healthcare expenditure, increasing demand for generic medicines, and expansion in chronic disease treatment segments. India remains a major supplier of generic medicines to global markets, particularly regulated regions such as the US and Europe.

    • Growth in pharmaceutical distribution and marketing businesses is being supported by increasing penetration of healthcare services in semi-urban and rural regions, along with higher awareness regarding preventive healthcare and prescription-based treatments.

    • Asset-light pharmaceutical marketing models, where products are manufactured through third-party facilities, continue to be adopted by companies seeking operational scalability with lower capital expenditure requirements.

    • The sector is also witnessing increased focus on specialty therapies, chronic care medicines, and branded generics, supported by changing disease patterns and ageing demographics.

    • However, the industry continues to face challenges from fluctuations in raw material prices, supply chain disruptions, regulatory compliance requirements, and pricing controls on essential medicines.
       

    Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your IPO allotment status for Goldline Pharmaceutical IPO.

    Explore Other IPOs

    • Current IPOs
    • Upcoming IPOs
    • Closed IPOs
    • IPO Performance
    • All
    • MainBoard
    • SME
    LEAP INDIA LIMITED IPO
    icon
    Closing Today
    SME IPO
    Early Access
    Bidding Period
    7th Aug 2026 - 8th Aug 2026
    Price Range
    ₹151.0 - 159.0
    IPO Size
    ₹24,80,00,00,000
    OPTIMYSTIX ENTERTAINMENT INDIA LIMITED IPO
    icon
    Closing Today
    SME IPO
    Early Access
    Bidding Period
    7th Aug 2026 - 8th Aug 2026
    Price Range
    ₹166.0 - 175.0
    IPO Size
    ₹1,08,49,99,936
    TECHNOCRAFT VENTURES LIMITED IPO
    icon
    Closing Today
    SME IPO
    Early Access
    Bidding Period
    7th Aug 2026 - 8th Aug 2026
    Price Range
    ₹200.0 - 212.0
    IPO Size
    ₹2,51,88,00,128
    MOLBIO DIAGNOSTICS LIMITED IPO
    icon
    Closing Tomorrow
    SME IPO
    Early Access
    Bidding Period
    10th Aug 2026 - 8th Aug 2026
    Price Range
    ₹768.0 - 807.0
    IPO Size
    ₹9,39,70,00,192
    DHOOT TRANSMISSION LIMITED IPO
    icon
    Closing Tomorrow
    SME IPO
    Early Access
    Bidding Period
    10th Aug 2026 - 8th Aug 2026
    Price Range
    ₹829.0 - 871.0
    IPO Size
    ₹30,66,88,98,304
    FASCINATE TEXTILES LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    11th Aug 2026 - 8th Aug 2026
    Price Range
    ₹148.0 - 156.0
    IPO Size
    ₹66,98,00,064
    Bidding Period
    11th Aug 2026 - 8th Aug 2026
    Price Range
    ₹133.0 - 140.0
    IPO Size
    ₹15,53,00,00,384
    SHAM FOAM LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    11th Aug 2026 - 8th Aug 2026
    Price Range
    ₹130.0 - 130.0
    IPO Size
    ₹40,48,00,000
    SHIPROCKET LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    12th Aug 2026 - 8th Aug 2026
    Price Range
    ₹92.0 - 97.0
    IPO Size
    ₹16,17,49,00,224
    Bidding Period
    12th Aug 2026 - 8th Aug 2026
    Price Range
    ₹271.0 - 285.0
    IPO Size
    ₹3,01,61,99,936
    PRAMODINI MEDICARE LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    12th Aug 2026 - 8th Aug 2026
    Price Range
    ₹110.0 - 118.0
    IPO Size
    ₹69,04,00,000
    • All
    • MainBoard
    • SME
    QANDT Foods Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    12th Aug 2026 - 8th Aug 2026
    Price Range
    ₹115.0 - 115.0
    IPO Size
    ₹26,25,00,000
    Bidding Period
    13th Aug 2026 - 8th Aug 2026
    Price Range
    ₹179.0 - 189.0
    IPO Size
    ₹93,90,00,000
    ENS Enterprises Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    14th Aug 2026 - 8th Aug 2026
    Price Range
    ₹87.0 - 92.0
    IPO Size
    ₹0
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    AceVector Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Advanced SysTek Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Advanta Enterprises Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Agilus Diagnostics Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    AGS Health Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Airox Technologies Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Ajay Poly Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Allchem Lifescience Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Annu Projects Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    AOne Steels India Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    NO ACTIVE IPO HERE
    • All
    • MainBoard
    • SME
    LAPL AUTOMOTIVE LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    6th Aug 2026 - 8th Aug 2026
    Price Range
    ₹88.0 - 94.0
    IPO Size
    ₹32,40,00,000
    ARDEE INDUSTRIES LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    5th Aug 2026 - 8th Aug 2026
    Price Range
    ₹50.0 - 53.0
    IPO Size
    ₹4,25,87,00,032
    G V ELECTRICALS LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    31st Jul 2026 - 8th Aug 2026
    Price Range
    ₹123.0 - 130.0
    IPO Size
    ₹42,25,00,000
    AEGEUS TECHNOLOGIES LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    4th Aug 2026 - 8th Aug 2026
    Price Range
    ₹100.0 - 105.0
    IPO Size
    ₹23,70,99,984
    Bidding Period
    3rd Aug 2026 - 8th Aug 2026
    Price Range
    ₹257.0 - 270.0
    IPO Size
    ₹1,77,80,99,968
    Bidding Period
    31st Jul 2026 - 8th Aug 2026
    Price Range
    ₹151.0 - 159.0
    IPO Size
    ₹39,04,00,000
    DHAVAL PACKAGING LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    30th Jul 2026 - 8th Aug 2026
    Price Range
    ₹92.0 - 97.0
    IPO Size
    ₹36,36,00,000
    JUNIPER GREEN ENERGY LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    30th Jul 2026 - 8th Aug 2026
    Price Range
    ₹214.0 - 225.0
    IPO Size
    ₹17,99,99,98,976
    MV ELECTROSYSTEMS LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    30th Jul 2026 - 8th Aug 2026
    Price Range
    ₹400.0 - 425.0
    IPO Size
    ₹2,90,00,00,000
    Bidding Period
    30th Jul 2026 - 8th Aug 2026
    Price Range
    ₹91.0 - 96.0
    IPO Size
    ₹27,65,00,000
    Bidding Period
    29th Jul 2026 - 7th Jul 2026
    Price Range
    ₹560.0 - 590.0
    IPO Size
    ₹92,75,21,99,680
    H R HYGIENE PRODUCTS LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    29th Jul 2026 - 7th Jul 2026
    Price Range
    ₹83.0 - 88.0
    IPO Size
    ₹53,95,00,032
    Bidding Period
    28th Jul 2026 - 7th Jul 2026
    Price Range
    ₹285.0 - 301.0
    IPO Size
    ₹1,59,83,00,032
    Bidding Period
    27th Jul 2026 - 7th Jul 2026
    Price Range
    ₹65.0 - 69.0
    IPO Size
    ₹28,57,00,000
    ADVANCE TECHNOFORGE LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    27th Jul 2026 - 7th Jul 2026
    Price Range
    ₹95.0 - 95.0
    IPO Size
    ₹24,03,00,000
    Bidding Period
    24th Jul 2026 - 7th Jul 2026
    Price Range
    ₹123.0 - 133.0
    IPO Size
    ₹82,43,00,032
    LOHIA CORP LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    23rd Jul 2026 - 7th Jul 2026
    Price Range
    ₹404.0 - 425.0
    IPO Size
    ₹11,01,29,00,864
    INDOMIM LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    23rd Jul 2026 - 7th Jul 2026
    Price Range
    ₹461.0 - 485.0
    IPO Size
    ₹38,12,12,01,664
    XTRANET TECHNOLOGIES LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    23rd Jul 2026 - 7th Jul 2026
    Price Range
    ₹120.0 - 127.0
    IPO Size
    ₹1,66,80,00,000
    CUBE HIGHWAYS TRUST IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    22nd Jul 2026 - 7th Jul 2026
    Price Range
    ₹151.0 - 152.0
    IPO Size
    ₹49,99,99,98,976
    • All
    • MainBoard
    • SME
    Issue Prize
    270.00
    Listing Day Close
    346.10(28.15%)
    Issue Prize
    159.00
    Listing Day Close
    166.75(5.03%)
    DHAVAL PACKAGING LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    97.00
    Listing Day Close
    111.68(15.46%)
    JUNIPER GREEN ENERGY LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    225.00
    Listing Day Close
    259.60(15.56%)
    MV ELECTROSYSTEMS LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    425.00
    Listing Day Close
    622.75(46.59%)
    Issue Prize
    96.00
    Listing Day Close
    126.00(31.25%)
    Issue Prize
    590.00
    Listing Day Close
    666.70(13.05%)
    H R HYGIENE PRODUCTS LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    88.00
    Listing Day Close
    87.97(0.00%)
    Issue Prize
    301.00
    Listing Day Close
    493.50(64.12%)
    Issue Prize
    69.00
    Listing Day Close
    57.15(-17.39%)
    ADVANCE TECHNOFORGE LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    95.00
    Listing Day Close
    89.30(-6.32%)
    Issue Prize
    133.00
    Listing Day Close
    126.55(-4.51%)
    LOHIA CORP LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    425.00
    Listing Day Close
    494.65(16.47%)
    INDOMIM LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    485.00
    Listing Day Close
    741.80(52.99%)
    XTRANET TECHNOLOGIES LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    127.00
    Listing Day Close
    124.80(-1.57%)
    CUBE HIGHWAYS TRUST IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    152.00
    Listing Day Close
    156.88(3.29%)
    Issue Prize
    70.00
    Listing Day Close
    126.35(80.00%)
    METALIC TECHNOFORGE LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    77.00
    Listing Day Close
    83.05(7.79%)
    GULF LLOYDS INDIA LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    100.00
    Listing Day Close
    95.00(-5.00%)
    Issue Prize
    424.00
    Listing Day Close
    528.50(24.76%)

    Frequently Asked Questions

    What is Goldline Pharmaceutical Ltd IPO?

    Answer Field

    Goldline Pharmaceutical Ltd IPO is a SME IPO of 27,00,000 equity shares of a face value of ₹10 aggregating up to ₹11.61 Crores. The issue is priced at ₹41 to ₹43 per share. The minimum order quantity is 3000 Shares. The IPO opens on May 12, 2026, and closes on May 14, 2026. Bigshare Services Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE-SME.

    When Goldline Pharmaceutical Ltd IPO will open?

    Answer Field

    The Goldline Pharmaceutical Ltd IPO opens on May 12, 2026 and closes on May 14, 2026.

    What is the lot size of Goldline Pharmaceutical Ltd?

    Answer Field

    Goldline Pharmaceutical Ltd lot size is 3000 shares, and the minimum amount required is ₹2,58,000.

    How to apply for Goldline Pharmaceutical Ltd IPO?

    Answer Field

    You can apply in Goldline Pharmaceutical Ltd IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. To apply for an IPO:

    • Login to Bajaj Broking account App/Website & click on IPO
    • Enter the number of lots and price at which you wish to apply.
    • Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
    • You will receive a mandate notification to block funds in your UPI app.
    • Approve the mandate request on your UPI and funds will be blocked.

    When is Goldline Pharmaceutical Ltd IPO allotment?

    Answer Field

    The finalization of Basis of Allotment for Goldline Pharmaceutical Ltd IPO will be done on May 15, 2026, and the allotted shares will be credited to your demat account by May 18, 2026.

    When is Goldline Pharmaceutical Ltd IPO listing date?

    Answer Field

    The Goldline Pharmaceutical Ltd listing date is May 19, 2026.

    Who is the registrar of Goldline Pharmaceutical Ltd IPO?

    Answer Field

    The registrar of Goldline Pharmaceutical Ltd IPO is Bigshare Services Pvt Ltd

    Which company is the book-running lead manager of the IPO?

    Answer Field

    Cumulative Capital Private Limited will be the book-running lead manager of this IPO.

    What is the fresh issue of Goldline Pharmaceutical Ltd IPO?

    Answer Field

    The fresh issue size is ₹11.61 Crores equity shares.

    What minimum lot size can retail subscribers subscribe to Goldline Pharmaceutical Ltd?

    Answer Field

    Retail investors can subscribe to a minimum of one lot, 3000 shares and ₹2,58,000 amount.

    How can I approve the UPI mandate request for Goldline Pharmaceutical Ltd IPO?

    Answer Field

    To apply for Goldline Pharmaceutical Ltd IPO, you need to log in to your demat account to complete the bidding process. Then, approve the payment mandate on your UPI app.

    What is the price range of Goldline Pharmaceutical Ltd?

    Answer Field

    The price of each Goldline Pharmaceutical Ltd share will be ranging in between ₹41 to ₹43 per share.

    What is the cut-off time for the UPI mandate for Goldline Pharmaceutical Ltd IPO?

    Answer Field

    The cut-off time for the UPI mandate confirmation is 5:00 PM, May 14, 2026.

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |